메뉴 건너뛰기




Volumn 26, Issue 11, 2009, Pages 1024-1034

Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease

Author keywords

Chronic obstructive pulmonary disease; Formoterol; Long acting beta 2 agonist; Maintenance therapy; Nebulization; Tiotropium

Indexed keywords

FORMOTEROL FUMARATE; PERFOROMIST; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; SCOPOLAMINE DERIVATIVE;

EID: 77949882083     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0080-z     Document Type: Article
Times cited : (7)

References (34)
  • 1
    • 84868337504 scopus 로고    scopus 로고
    • Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
    • Update. National Institutes of Health/WHO. Available at:, Accessed January 5, 2009
    • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2008 Update. National Institutes of Health/WHO. Available at: http://www.goldcopd.org. Accessed January 5, 2009.
    • (2008) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
  • 2
    • 0035446985 scopus 로고    scopus 로고
    • Inhaled formoterol; dry powder versus ipratropium bromide in chronic obstructive pulmonary disease
    • Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol; dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784.
    • (2001) Am J Respir Crit Care Med , vol.164 , pp. 778-784
    • Dahl, R.1    Greefhorst, L.A.P.M.2    Nowak, D.3
  • 3
    • 0036014549 scopus 로고    scopus 로고
    • Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial
    • Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936-943.
    • (2002) Eur Respir J , vol.19 , pp. 936-943
    • Aalbers, R.1    Ayres, J.2    Backer, V.3
  • 4
    • 37449007559 scopus 로고    scopus 로고
    • Efficacy and safety of formoterol fumurate delivered by nebulization to COPD patients
    • Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumurate delivered by nebulization to COPD patients. Respir Med. 2008;102:189-197.
    • (2008) Respir Med , vol.102 , pp. 189-197
    • Gross, N.J.1    Nelson, H.S.2    Lapidus, R.J.3
  • 5
    • 36248991849 scopus 로고    scopus 로고
    • Cardiovascular safety of nebulized formoterol: Results of a placebo-controlled, double-blind phase III study
    • Nelson HS, Gross NJ, Rinehart M, et al. Cardiovascular safety of nebulized formoterol: results of a placebo-controlled, double-blind phase III study. Clin Ther. 2007;29:2167-2178.
    • (2007) Clin Ther , vol.29 , pp. 2167-2178
    • Nelson, H.S.1    Gross, N.J.2    Rinehart, M.3
  • 6
    • 68749083915 scopus 로고    scopus 로고
    • Longterm safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
    • Donohue JF, Hanania NA, Fogarty C, et al. Longterm safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008;2:199-208.
    • (2008) Ther Adv Respir Dis , vol.2 , pp. 199-208
    • Donohue, J.F.1    Hanania, N.A.2    Fogarty, C.3
  • 7
    • 0036181956 scopus 로고    scopus 로고
    • A longterm evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
    • Casaburi R, Mahler DA, Jones PW, et al. A longterm evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
    • (2002) Eur Respir J , vol.19 , pp. 217-224
    • Casaburi, R.1    Mahler, D.A.2    Jones, P.W.3
  • 8
    • 34547618224 scopus 로고    scopus 로고
    • Efficacy and safety of tiotropium in COPD patients in primary care - The SPiRiva Usual CarE (SPRUCE) study
    • Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respir Res. 2007;8:45.
    • (2007) Respir Res , vol.8 , pp. 45
    • Freeman, D.1    Lee, A.2    Price, D.3
  • 9
    • 0141990930 scopus 로고    scopus 로고
    • Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease
    • Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58: 855-860.
    • (2003) Thorax , vol.58 , pp. 855-860
    • Calverley, P.M.1    Lee, A.2    Towse, L.3    Van, N.J.4    Witek, T.J.5    Kelsen, S.6
  • 10
    • 53749102775 scopus 로고    scopus 로고
    • A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    • Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;249:1616-1618.
    • (2008) N Engl J Med. , vol.249 , pp. 1616-1618
    • Tashkin, D.P.1    Celli, B.2    Senn, S.3
  • 11
    • 33847313718 scopus 로고    scopus 로고
    • Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease
    • Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy. 2007;27: 447-454.
    • (2007) Pharmacotherapy , vol.27 , pp. 447-454
    • Nichols, J.1
  • 12
    • 0345414503 scopus 로고    scopus 로고
    • The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
    • Cazzola M, Santus P, Di Marco F, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17:35-39.
    • (2004) Pulm Pharmacol Ther , vol.17 , pp. 35-39
    • Cazzola, M.1    Santus, P.2    Di Marco, F.3
  • 13
    • 23144457098 scopus 로고    scopus 로고
    • Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    • van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;20:214-222.
    • (2005) Eur Respir J , vol.20 , pp. 214-222
    • Van Noord, J.A.1    Aumann, J.-L.2    Janssens, E.3
  • 14
    • 33645116728 scopus 로고    scopus 로고
    • Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    • van Noord JA, Aumann J-L, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129:509-517.
    • (2006) Chest , vol.129 , pp. 509-517
    • Van Noord, J.A.1    Aumann, J.-L.2    Janssens, E.3
  • 15
    • 61649115167 scopus 로고    scopus 로고
    • Formoterol and tiotropium compared with tiotropium alone for treatment of COPD
    • Tashkin DP, Pearle J, Iazzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6:17-25.
    • (2009) COPD , vol.6 , pp. 17-25
    • Tashkin, D.P.1    Pearle, J.2    Iazzoni, D.3    Varghese, S.T.4
  • 16
    • 33749330419 scopus 로고    scopus 로고
    • Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: A pilot study
    • Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med. 2006;100:1925-1932.
    • (2006) Respir Med , vol.100 , pp. 1925-1932
    • Di Marco, F.1    Verga, M.2    Santus, P.3
  • 17
    • 55749112997 scopus 로고    scopus 로고
    • Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
    • Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-1520.
    • (2008) Respir Med , vol.102 , pp. 1511-1520
    • Vogelmeier, C.1    Kardos, P.2    Harari, S.3
  • 18
    • 40249111478 scopus 로고    scopus 로고
    • Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial
    • Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102:479-487.
    • (2008) Respir Med , vol.102 , pp. 479-487
    • Tashkin, D.P.1    Littner, M.2    Andrews, C.P.3
  • 19
    • 67649317017 scopus 로고    scopus 로고
    • Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide
    • Hanania NA, Boota A, Kerwin E, et al. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide. Drugs. 2009;69:1205-1216.
    • (2009) Drugs , vol.69 , pp. 1205-1216
    • Hanania, N.A.1    Boota, A.2    Kerwin, E.3
  • 20
    • 0026871146 scopus 로고
    • A selfcomplete measure for chronic airflow limitation - The St. George's Respiratory Questionnaire
    • Jones PW, Quirk FJ, Baveystock CM, et al. A selfcomplete measure for chronic airflow limitation - the St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321-1327.
    • (1992) Am Rev Respir Dis , vol.145 , pp. 1321-1327
    • Jones, P.W.1    Quirk, F.J.2    Baveystock, C.M.3
  • 21
    • 20144378063 scopus 로고    scopus 로고
    • Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD
    • Mahler DA, Ward J, Ferrio-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1:165-172.
    • (2004) COPD , vol.1 , pp. 165-172
    • Mahler, D.A.1    Ward, J.2    Ferrio-Carrion, G.3
  • 22
    • 0021256105 scopus 로고
    • The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
    • Mahler DA, Weinberg CH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-758.
    • (1984) Chest , vol.85 , pp. 751-758
    • Mahler, D.A.1    Weinberg, C.H.2    Wells, C.K.3
  • 23
    • 20144362569 scopus 로고    scopus 로고
    • St. George's Respiratory Questionnaire: MCID
    • Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2:75-79.
    • (2005) COPD , vol.2 , pp. 75-79
    • Jones, P.W.1
  • 24
    • 20144382361 scopus 로고    scopus 로고
    • Minimal clinically important differences in COPD lung function
    • Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2: 111-124.
    • (2005) COPD , vol.2 , pp. 111-124
    • Donohue, J.F.1
  • 25
    • 33646042213 scopus 로고    scopus 로고
    • Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD
    • Oga T, Nishimura K, Mitsuhiro T, et al. Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD. Respir Med. 2006;100:965-971.
    • (2006) Respir Med , vol.100 , pp. 965-971
    • Oga, T.1    Nishimura, K.2    Mitsuhiro, T.3
  • 26
    • 0037322464 scopus 로고    scopus 로고
    • Minimal important difference of the transition dyspnoea index in a multinational clinical trial
    • Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21:267-272.
    • (2003) Eur Respir J , vol.21 , pp. 267-272
    • Witek Jr., T.J.1    Mahler, D.A.2
  • 27
    • 55649089631 scopus 로고    scopus 로고
    • Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD
    • Terzano C, Petroianni A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med. 2008;102:1701-1707.
    • (2008) Respir Med , vol.102 , pp. 1701-1707
    • Terzano, C.1    Petroianni, A.2    Conti, V.3
  • 28
    • 60949104107 scopus 로고    scopus 로고
    • Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD
    • Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009;103:516-524.
    • (2009) Respir Med , vol.103 , pp. 516-524
    • Tashkin, D.P.1    Donohue, J.F.2    Mahler, D.A.3
  • 29
    • 49449094831 scopus 로고    scopus 로고
    • Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD
    • Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;34:255-262.
    • (2008) Chest , vol.34 , pp. 255-262
    • Rabe, K.F.1    Timmer, W.2    Sagkriotis, A.3
  • 30
    • 51049107684 scopus 로고    scopus 로고
    • Nebulized formoterol fumarate: Dose selection and pharmacokinetics
    • Gross NJ, Kerwin E, Levine B, et al. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008;21:818-823.
    • (2008) Pulm Pharmacol Ther , vol.21 , pp. 818-823
    • Gross, N.J.1    Kerwin, E.2    Levine, B.3
  • 31
    • 13544253826 scopus 로고    scopus 로고
    • Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology
    • Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
    • (2005) Chest , vol.127 , pp. 335-371
    • Dolovich, M.B.1    Ahrens, R.C.2    Hess, D.R.3
  • 32
    • 34247186876 scopus 로고    scopus 로고
    • Comparing COPD treatment: Nebulizer, metered dose inhaler, and concomitant therapy
    • Tashkin DP, Klein GL, Colman SS, et al. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Amer J Med. 2007;120:435-441.
    • (2007) Amer J Med , vol.120 , pp. 435-441
    • Tashkin, D.P.1    Klein, G.L.2    Colman, S.S.3
  • 33
    • 67649380868 scopus 로고    scopus 로고
    • Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI
    • Sutherland ER, Brazinsky S, Feldman G, et al. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin. 2009;25:653-661.
    • (2009) Curr Med Res Opin , vol.25 , pp. 653-661
    • Sutherland, E.R.1    Brazinsky, S.2    Feldman, G.3
  • 34
    • 0036591408 scopus 로고    scopus 로고
    • Survey of patients' views of domiciliary nebulizer treatment for chronic lung disease
    • Barta SK, Crawford A, Roberts CM. Survey of patients' views of domiciliary nebulizer treatment for chronic lung disease. Respir Med. 2002;96: 375-381.
    • (2002) Respir Med , vol.96 , pp. 375-381
    • Barta, S.K.1    Crawford, A.2    Roberts, C.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.